Results 21 to 30 of about 113,281 (294)
Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis [PDF]
Endocrinology and Metabolism, 2023 Background The effects of dipeptidyl peptidase 4 (DPP-4) inhibitors over the course of long-term treatment remain unclear, and concerns have been raised regarding the role of DPP-4 inhibitors in carcinogenesis in the pancreas.
Mee Kyoung Kim +3 more
doaj +1 more source
BMC Endocrine Disorders, 2019 Background Dipeptidyl peptidase-4 (DPP-4) inhibitors could effectively reduce HbA1C and postprandial hyperglycemia and could incur only minimal danger of hypoglycemia.
Fu-Shun Yen +6 more
doaj +1 more source
Clinical Case Reports, 2020 We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara +8 more
doaj +1 more source
Characterization of Schnurri : an integral component of the Dpp-signaling pathway in "Drosophila melanogaster" [PDF]
, 2004 Signaling by the transforming growth factor-β (TGF-β) family of ligands plays a crucial role during development and tissue homeostasis in all multicellular organisms. The signal transduction pathway is highly conserved and relatively simple.
Hartmann, Britta
core +1 more source
The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure
Journal of Pharmacological Sciences, 2017 Dipeptidyl peptidase-4 (DPP-4) inhibitors are hypoglycemic agents. DPP-4 inhibitor has cardioprotective effects after transverse aortic constriction (TAC), but role of DPP-4 on cardiac fibrosis after TAC is not well known.
Masanori Hirose +6 more
doaj +1 more source
DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy? [PDF]
Diabetes, 2014 There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade.
Usha, Panchapakesan, Carol A, Pollock
openaire +2 more sources
Frontiers in Endocrinology, 2021 AimAt present, daily DPP-4 inhibitors are quite frequently prescribed in subjects with type 2 diabetes mellitus (T2DM). Recently, it has been drawing much attention that once-weekly incretin-based injection dulaglutide was developed.
Junpei Sanada +14 more
doaj +1 more source
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin [PDF]
Diabetes & Metabolism Journal, 2015 BackgroundDipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU).
Ye An Kim +9 more
doaj +1 more source
Cardiovascular effects of the DPP-4 inhibitors
Diabetes and Vascular Disease Research, 2012 Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP.
Tessey, Jose, Silvio E, Inzucchi
openaire +2 more sources
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
World Journal of Diabetes, 2022 SGLT-2 inhibitors (SGLT-2Is) have significantly improved cardio-renal outcomes and are preferred agents in people with cardiovascular diseases, heart failure, and diabetic kidney disease. Similarly, GLP-1 receptor agonists (GLP-1RAs) have significantly improved atherosclerotic cardiovascular outcomes. To this end, DPP-4 inhibitors (DPP-4Is) are cardiac-
Singh, Awadhesh Kumar, Singh, Ritu
openaire +2 more sources